Barclays initiated coverage of Jazz Pharmaceuticals (JAZZ) with an Overweight rating and $224 price target The firm says its key opinion leader calls suggest Jazz’s central nervous system base business is “sticky.” Barclays also sees “oncology-fueled” Ziihera growth in multiple tumor types longer term with important readouts in 2027 for Jazz.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $226 from $225 at Morgan Stanley
- Jazz Pharmaceuticals price target raised to $255 from $210 at Deutsche Bank
- Jazz Pharmaceuticals price target raised to $275 from $263 at BofA
- Jazz Pharmaceuticals price target raised to $250 from $235 at Wells Fargo
- Jazz Pharmaceuticals: Underappreciated Growth Story with Durable Sleep Franchise and Pipeline-Driven Upside